Wellington Management Group LLP Boosts Stake in Eli Lilly

Investment firm increases holding in pharmaceutical giant by 4.1% in Q3

Mar. 14, 2026 at 11:53am

Got story updates? Submit your updates here. ›

According to a recent SEC filing, Wellington Management Group LLP increased its stake in Eli Lilly and Company (NYSE: LLY) by 4.1% in the third quarter of 2026. The investment firm now owns 14,563,780 shares of the pharmaceutical company's stock, valued at over $11.11 billion and representing 1.54% of Eli Lilly's outstanding shares.

Why it matters

This significant increase in Wellington's position in Eli Lilly reflects the investment firm's confidence in the pharmaceutical company's growth potential. As one of Eli Lilly's largest institutional investors, Wellington's move could signal broader market optimism around the company's product pipeline and financial performance.

The details

According to the SEC filing, Wellington Management Group purchased an additional 574,229 shares of Eli Lilly during the third quarter, bringing its total stake to 14,563,780 shares. This represents approximately 1.54% of Eli Lilly's total outstanding shares. Wellington Management is one of the largest asset management firms in the world, with over $1 trillion in assets under management.

  • Wellington Management Group filed the 13F report disclosing the increased stake in Eli Lilly on March 14, 2026.

The players

Wellington Management Group LLP

A global investment management firm with over $1 trillion in assets under management, serving institutional and private clients worldwide.

Eli Lilly and Company

A multinational pharmaceutical company headquartered in Indianapolis, Indiana, that develops and markets drugs in various therapeutic areas including diabetes, oncology, immunology, and neuroscience.

Got photos? Submit your photos here. ›

The takeaway

Wellington Management Group's increased stake in Eli Lilly underscores the investment firm's confidence in the pharmaceutical company's long-term growth prospects. As one of Eli Lilly's largest institutional investors, Wellington's move could signal broader market optimism around the company's product pipeline and financial performance.